Welcome to our dedicated page for CLOVER HEALTH INVESTMENTS /DE SEC filings (Ticker: CLOV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CLOVER HEALTH INVESTMENTS /DE's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CLOVER HEALTH INVESTMENTS /DE's regulatory disclosures and financial reporting.
Clover Health Investments, Corp. (CLOV) received a notice that stockholder Jamie Reynoso intends to sell up to 8,691 shares of Class A common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $40,500.06 based on recent prices and with 435,441,337 shares of this class outstanding.
The shares relate to restricted stock units and the filing states the planned sale is a non‑discretionary “sell to cover” transaction to satisfy tax withholding obligations upon vesting and settlement, rather than a voluntary reduction in investment. The notice also lists prior 10b5‑1 plan sales by Reynoso over the past three months.
CLOVER HEALTH INVESTMENTS, CORP. (CLOV) received a notice that former officer Brady Priest intends to sell up to 215,291 shares of common stock under Rule 144 through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $999,574.58 as of September 15, 2026.
The notice also lists prior sales of CLOV common stock by Brady Priest during the preceding three months totaling several hundred thousand shares.
Clover Health Investments, Corp. (CLOV) has a notice from officer Conrad Wai to sell shares of the company’s common stock under Rule 144. The planned sale covers 300,000 shares of common stock through Merrill Private Wealth Management on or after September 15, 2026, listed on NASDAQ.
The 300,000 shares correspond to multiple tranches of RSUs scheduled to settle in cash and stock between October 31, 2024 and April 30, 2025. The notice also reports that Wai sold 24,215 shares of common stock in the prior three months on July 15, 2026.
Clover Health Investments (CLOV) reported that Joseph Frank Oldakowski, its VP of Finance and Controller, sold 20,000 shares of Class A Common Stock on September 14, 2026 at $5.16 per share in an open-market or private transaction. Following this sale, he continues to hold 279,067 shares directly.
CLOVER HEALTH INVESTMENTS, CORP. (CLOV) received a notice that officer Joseph Frank Oldakowski intends to sell 20,000 shares of common stock under Rule 144. The proposed sale, through Morgan Stanley Smith Barney LLC on NASDAQ, is valued at approximately $103,100 based on the figures disclosed. During the prior three months, Oldakowski sold 12,102 shares for about $58,769.73.
Clover Health Investments, Corp. (symbol CLOV) received a Rule 144 notice from officer Brady Priest covering planned sales of up to 73,516 shares of common stock, with an indicated aggregate market value of $305,113.45, around 08/31/2026. The notice cites 435,441,337 common shares outstanding. It also reports that Priest sold 474,801 shares for an aggregate $2,171,597.33 on 08/14/2026 and 441,601 shares for $2,141,988.87 on 08/07/2026, all as common stock transactions under Rule 144.
CLOVER HEALTH INVESTMENTS, CORP. (CLOV) furnished a supplemental shareholder Q&A alongside its second quarter 2026 results, expanding on its business model, technology platform and outlook. Management highlights that members in year three generate ~$155 PMPM more insurance gross profit than in year one, and that Clover Assistant–managed members show an ~18% better medical cost ratio by year three versus non–Clover Assistant members. Clinical analyses in chronic kidney disease show CA-powered care associated with diagnosis 18 months earlier, at an average GFR of 52.6 vs. 46.5 mL/min, and a slowing of kidney function decline from 4.6 to 1.3 mL/min per year, about a 72% slower rate.
The company notes that ~49% of its membership is still in years one and two of maturity, emphasizing potential cohort improvement over time under its full-risk model. It reports Medicare Advantage market share in New Jersey of ~31% on an individual non-SNP basis and reiterates a strategy of deepening density in core markets like New Jersey and Georgia while scaling its Counterpart Health platform. Clover states that its PPO and HMO plans are rated 4.5 Stars for the 2027 payment year and that it is actively litigating an appeal related to Star ratings, while focusing on expanding Clover Assistant adoption, AI-driven operating efficiencies and long-term earnings potential.
Clover Health Investments, Corp. (CLOV) insider Joseph Clay, Interim CFO, reported selling 17,775 shares of Class A Common Stock on August 17, 2026 at a weighted average price of $4.39 per share. According to the company’s equity plan, this was a mandated “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting of 6.25% of previously granted RSUs on August 16, 2026, and is described as non-discretionary. After the sale, Clay directly held 1,249,526 shares, and the remaining RSUs continue to vest quarterly in 6.25% increments through February 16, 2028, subject to continued service. The filing affirms that the transaction was effected under a Rule 10b5-1 trading plan.
Clover Health Investments Corp. (CLOV) reports a planned transaction involving Class A Common Stock held through Morgan Stanley Smith Barney LLC. The filing lists 16,942 shares linked to restricted stock units granted on August 16, 2026 as compensation from the issuer.
It also notes a prior sale of 4,630 Class A shares on July 15, 2026 for a reported amount of $21,622.10, executed as a 10b5-1 Plan Sale by Joseph Clay Thornton.
A shareholder has filed to sell common stock. A holder working through Morgan Stanley Smith Barney LLC Executive Financial Services registered up to 474,801 common shares, with an aggregate market value of $2,171,597.33, for potential sale on or after 08/14/2026 on NASDAQ. The filing also lists multiple restricted stock and performance share awards from the issuer and discloses prior sales within the last three months.